Dott. Ielasi discusses about the results of the 2 years clinical outcomes of the HYPER Study and the benefits of RESTORE® DEB
Dott. Ielasi (Milan, Italy) speaks to Radcliffe at EuroPCR 2023 congress held in Paris (France) about the results of the Hyper Study 2-years Follow-up.
In this video interview, Dott. Ielasi summarizes the benefits of RESTORE® paclitaxel eluting balloon and comments the results of the Hyper study at 2 years, putting a focus on the encouraging results of the combined use of modern DES and RESTORE® DEB in the context of de novo diffuse CAD: in detail, results showed a 2-year clinical follow-up available for the vast majority of the patients enrolled (n=105/106, 99%) and a low incidence of Device oriented Composite Endpoint (DoCE) equal to 4.6% at 24 months.
In conclusion, even if larger and more robust data from RCTs (vs. full metal jacket PCIs) are needed to confirm the findings, the HYPER study reports very encouraging results in terms of safety and efficacy of the hybrid approach in the treatment of diffuse CAD.